Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 0.53 |
| ▸ | TOP2A | P11388 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1212648 | 0.98 | ALOX15 (0.55) | ALOX15TOP2AALDH1A1TRPV1HDAC1 | |
| SCHEMBL1216409 | 0.94 | ALOX15 (0.52) | ALOX15ALDH1A1TRPV1HDAC1HDAC6 | |
| SCHEMBL1216560 | 0.94 | ALOX15 (0.49) | ALOX15TOP2AALDH1A1TRPV1HDAC1 | |
| SCHEMBL1216124 | 0.94 | ALOX15 (0.53) | ALOX15TOP2AALDH1A1TRPV1HDAC1 | |
| SCHEMBL1216101 | 0.92 | ALOX15 (0.56) | ALOX15TOP2AALDH1A1TRPV1CNR1 | |
| SCHEMBL1217823 | 0.92 | ALOX15 (0.55) | ALOX15TOP2AALDH1A1TRPV1HDAC1 | |
| SCHEMBL1215304 | 0.91 | ALOX15 (0.55) | ALOX15TOP2AALDH1A1TRPV1 | |
| SCHEMBL1218413 | 0.91 | ALOX15 (0.43) | ALOX15HDAC1HDAC6 | |
| SCHEMBL1214517 | 0.91 | ALOX15 (0.54) | ALOX15TOP2AALDH1A1TRPV1HDAC1 | |
| SCHEMBL1218395 | 0.91 | ALOX15 (0.50) | ALOX15HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028544-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-7829592-B2 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | XENOPORT, INC. (US) | 2010-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028544-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | COMT, PARK7, DDT | ALOX15 513/4885TOP2A 2204/4885ALDH1A1 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.